Spago Nanomedical AB (XSAT:SPAG BTA) FCF Margin % : -1,901.18% (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Spago Nanomedical AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Spago Nanomedical AB's Free Cash Flow for the three months ended in Mar. 2025 was kr-6.43 Mil. Spago Nanomedical AB's Revenue for the three months ended in Mar. 2025 was kr0.34 Mil. Therefore, Spago Nanomedical AB's FCF Margin % for the quarter that ended in Mar. 2025 was -1,901.18%.

As of today, Spago Nanomedical AB's current FCF Yield % is -29.85%.

The historical rank and industry rank for Spago Nanomedical AB's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Spago Nanomedical AB was -1826.16%. The lowest was -131673.33%. And the median was -6722.05%.

XSAT:SPAG BTA's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -102.06
* Ranked among companies with meaningful FCF Margin % only.

Spago Nanomedical AB FCF Margin % Historical Data

The historical data trend for Spago Nanomedical AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB FCF Margin % Chart

Spago Nanomedical AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-7,353.80

-6,090.30

-3,986.34

-3,775.15

-1,826.16

Spago Nanomedical AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
FCF Margin %	Get a 7-Day Free Trial															-3,011.43	-1,981.70	-1,572.37	-1,200.16	-1,901.18

Competitive Comparison of Spago Nanomedical AB's FCF Margin %

For the Biotechnology subindustry, Spago Nanomedical AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spago Nanomedical AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Spago Nanomedical AB's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Spago Nanomedical AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Spago Nanomedical AB's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-34.898	/	1.911
	=	-1,826.16 %

Spago Nanomedical AB's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	-6.426	/	0.338
	=	-1,901.18 %

Spago Nanomedical AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Spago Nanomedical AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (XSAT:SPAG BTA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

SPAGO:Sweden

Address

Scheelevagen 22, Lund, SWE, SE-223 63

Website

https://www.spagonanomedical.se

Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.

Spago Nanomedical AB Headlines

No Headlines